Vascular endothelial growth factor D(VEGF-D) antibodies and...

Details Vascular endothelial growth factor D(VEGF-D) antibodies and... Vascular endothelial growth factor D(VEGF-D) antibodies and...

2002-06-05

2008-08-12

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S001490, C424S139100, C424S141100, C424S145100, C424S158100, C530S387100, C530S387900, C530S388100, C530S388240, C530S391300

Reexamination Certificate

active

07410639

ABSTRACT:
VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5968778 (1999-10-01), Hoppe et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6235713 (2001-05-01), Achen et al.
patent: 6383484 (2002-05-01), Achen et al.
patent: 6689580 (2004-02-01), Achen et al.
patent: 6828426 (2004-12-01), Hirata et al.
patent: 7122654 (2006-10-01), Achen
patent: 2002/0123481 (2002-09-01), Oliviero
patent: 2003/0166547 (2003-09-01), Oliviero
patent: 0 539 748 (1993-05-01), None
patent: 0 578 909 (1994-01-01), None
patent: 9519928.7 (1995-09-01), None
patent: 9612368.2 (1996-06-01), None
patent: 0 935 001 (1999-08-01), None
patent: 1 283 268 (2003-02-01), None
patent: 0 956 339 (2005-10-01), None
patent: 8-185216 (1996-07-01), None
patent: 95/24473 (1995-09-01), None
patent: WO-95/24473 (1995-09-01), None
patent: WO-96/11269 (1996-04-01), None
patent: 96/26736 (1996-09-01), None
patent: 96/27007 (1996-09-01), None
patent: WO-96/26736 (1996-09-01), None
patent: WO-96/27007 (1996-09-01), None
patent: 96/39421 (1996-12-01), None
patent: WO-96/39421 (1996-12-01), None
patent: WO-97/05250 (1997-02-01), None
patent: 97/12972 (1997-04-01), None
patent: WO-97/12972 (1997-04-01), None
patent: 98/02543 (1998-01-01), None
patent: WO-98/02543 (1998-01-01), None
patent: 98/07832 (1998-02-01), None
patent: WO-98/07832 (1998-02-01), None
patent: 98/24811 (1998-06-01), None
patent: WO-98/24811 (1998-06-01), None
EMBO J, 1996, vol. 15, No. 2, pp. 290-298. Joukor et al.
Genomics, Jun. 15, 1997, vol. 42, pp. 483-488, Yamada et al.
Tischer, et al., Biochem. And Biophys. Research Communication, 163 (3) : 1198-1206, 1989.
Orlandini, et al., Proc. Natl. Acad. Of Science, USA 93:11675-11680, 1996.
Hillier, et al., GenBank Accession No. H24828, 1995.
U.S. Appl. No. 11/692,753, Achen et al.
U.S. Appl. No. 11/692,774, Achen et al.
U.S. Appl. No. 11/304,585, Achen et al.
U.S. Appl. No. 11/772,089, Achen et al.
Achen et al., “The Non-receptor Tyrosine Kinase Lyn is Localised in the Developing Murine Blood-brain Barrier,”Differentiation, 59:15-24 (1995).
Andersson et al., “Involvement of Loop 2 of Platelet-derived Growth Factor-AA and -BB in Receptor Binding,”Growth Factors, 12:159-164 (1995).
Andersson et al., “Assignment of Interchain Disulfide Bonds in Platelet-derived Growth Factor (PDGF) and Evidence for Agonist Activity of Monomeric PDGF,”J. Biol. Chem., 267:11260-11266 (1992).
Aruffo et al., “Molecular Cloning of a CD28 cDNA by a High-efficiency COS Cell Expression System,”PNAS, 84:8573-8577 (1987).
Cao et al., “gro-β, a -C-X-C- Chemokine, is an Angiogenesis Inhibitor that Suppresses the Growth of Lewis Lung Carcinoma in Mice,”J. Exp. Med., 182:2069-2077 (1995).
Claffey et al., “Structural Requirements for Dimerization, Glycosylation, Secretion, and Biological Function of VPF/VEGF,”Biochim. Biophys. Acta., 1246:1-9 (1995).
Dignam et al., “Balbiani Ring 3 inChironomus tentansEncodes a 185-k Da Secretory Protein which is Synthesized Throughout the Fourth Larval Instar,”Gene, 88:133-140 (1990).
Ferrara et al., “The Vascular Endothelial Growth Factor Family of Polypeptides,”J. Cell. Biochem., 47:211-218 (1991).
Flemming et al., “Reversion of Autocrine Transformation by a Dominant Negative Platelet-Derived Grwoth Factor Mutant,”Mol. Cell Biol., 13:4066-4076 (1993).
Folkman et al., “Angiogenesis,”J. Biol. Chem., 267:10931-10934 (1992).
Gospodarowicz et al., “Isolation and Characterization of a Vascular Endothelial Cell Mitogen Produced by Pituitary-derived Folliculo Stellate Cells,”PNAS, 86:7311-7315 (1989).
Haefliger et al., “Four Novel Members of the Connexin Family of Gap Junction Proteins,”J. Biol. Chem., 267:2057-2064 (1992).
Hatva et al., “Vascular Growth Factors and Receptors in Capillary Hemangioblastomas and Hemangiopericytomas,”Am. J. Pathol., 148(3):763.775 (1996).
Holloway et al., “Chromosomal Mapping of Five Highly Conserved Murine Homologues of theDrosphilaRing Finger GeneSeven-in-absentia,” Genomics, 41:160-168 (1997).
Houck et al., “Dual Regulaltion of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms,”J. Biol. Chem., 267(36):26031--26037 (1992).
Jenkins et al., “Organization, Distribution, and Stability of Endogenous Ecotropic Murine Leukemia Virus DNA Sequences in Chromosomes ofMus musculus,” J. Virol., 43:26-36 (1992).
Kaipainen et al., “Enhanced Expression of the Tie Receptor Tyrosine Kinase Messenger RNA in the Vascular Endothelium of Metastatic Melanomas,”Cancer Res., 54:6571-6577 (1994).
Kaipainen et al., “Expression of the Fms-like Tyrosine Kinase 4 Gene Becomes Restricted to Lymphatic Endothelium During Development,”PNAS, 92:3566-3570 (1995).
Kim et al., “The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies,”Growth Factors, 7:53-64 (1992).
Leung et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen,”Science, 246:1306-1309 (1989).
Montesano et al., “Basic Fibroblast Growth Factor Induces Angiogenesis in Vitro,”PNAS, 83:7297-7301 (1986).
Oefner et al., “Crystal Structure of Human Platelet-derived Growth Factor BB,”EMBO J., 11:3931-3926 (1992).
Oelrichs et al., “NYK/FLK-1: A Putative Receptor Protein Tyrosine Kinase Isolated from E10 Embryonic Neuroepithelium is Expressed in Endothelial Cells of the Developing Embryo,”Oncogene, 8:11-18 (1993).
Östman et al., “Identification of Three Amino Acids is the Platelet-derived Growth Factor (PDGF) B-chain that are Important for Binding to the PDGF β-Receptor,”J. Biol. Chem., 266:10073-10077 (1991).
Olofsson et al., “Vascular Endothelial Growth Factor B, a Novel Growth Factor for Endothelial Cells”PNAS, 93:2576-2581 (1996).
Patil et al., “DNA-based Therapeutics and DNA Delivery Systems: A Comprehensive Review,”AAPS Journal, 17:E61-E77 (2005).
Paulsson et al., “The Balbiani Ring 3 Gene inChironomus tentanshas a Diverged Repetitive Structure Split by Many Introns,”J. Mol. Biol., 211:331-349 (1990).
Plate et al., “Angiogenesis in Malignant Gliomas,”GLIA, 15(3):339-347 (1995).
Pötgens et al., “Covalent Dimerization of Vascular Permeability Factor/Vascular Endothelial Growth Factor is Essential for its Biological Activity,”J. Biol. Chem., 269:32879-32885 (1994).
Rastinejad et al., “Regulation of the Activity of a New Inhibitor of Angiogenesis by a Cancer Suppressor Gene,”Cell, 56:345-355 (1989).
Sambrook et al.,Molecular Cloning: A Laboratory Manual, 2nd Ed, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York(1989).
Sanger et al., “DNA Sequencing with Chain-terminating inhibitors,”PNAS, 74:5463-5467 (1977).
Stacker et al., “Biosynthesis of Vascular Endothelial Growth Factor-D Involves Proteolytic Processing which Generates Non-covalent Homodimers”,J. Biol. Chem., 274(45):32127-32136 (1999).
Strawn et al., “Fik-1 as a Target for Tumor Growth Inhibition,”Cancer Res., 56:3540-3545 (1996).
Hillier et al., GenBank Accession No. H24828 (1995).
Orlandini et al., “Identification of ac-fos-induced Gene that is Related to teh Platelet-derived Growth Factor/Vascular Endothelial Growth Factor Family,”PNAS, 93:11675-11680 (1996).

Affiliated with

Also associated with

Rating

Vascular endothelial growth factor D(VEGF-D) antibodies and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vascular endothelial growth factor D(VEGF-D) antibodies and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial growth factor D(VEGF-D) antibodies and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3993218